Preparation of magnetically responsive albumin nanospheres and in vitro drug release studies

Figures & data

Table I. DIC and DIE calculations, mean particle size and PDI of nanoparticles.

	DIC (mg/mg) × 10^3	DIE (%)	Mean particle size (nm)	PDI
Doxorubicin concentration (mg/ml)
0.5	11.9 ± 2.0	51.7 ± 4.1	111.6 ± 10.1	0.150 ± 0.012
1	29.5 ± 2.0	65.5 ± 4.6	129.5 ± 14.8	0.162 ± 0.010
1.5	45.8 ± 1.9	68.2 ± 3.0	186.2 ± 17.1	0.199 ± 0.012
2	60.2 ± 2.5	71.5 ± 3.2	211.5 ± 18.2	0.259 ± 0.019
2.5	76.8 ± 2.9	74.3 ± 3.0	369.0 ± 25.5	0.345 ± 0.011
Magnetite concentration (mg/ml)
1.5	26.1 ± 0.7	65.1 ± 1.8	209.4 ± 10.3	0.158 ± 0.018
3	22.3 ± 0.9	58.6 ± 2.4	210.0 ± 12.1	0.178 ± 0.020
5	21.3 ± 1.0	59.8 ± 2.8	211.0 ± 14.3	0.184 ± 0.012
7.5	20.9 ± 0.9	63.4 ± 3.8	348.2 ± 23.8	0.317 ± 0.025

Figure 1. Particle size and (A) desolvation efficiency of BSA-NPs at different BSA concentrations; (B) DOX incorporation efficiency of DOX-BSA-NPs at different DOX concentrations; and (C) DOX incorporation efficiency of M-DOX-BSA-NPs at different magnetite concentrations.

Figure 2. SEM images of (A) empty, (B) DOX-loaded and (C) DOX-unloaded magnetic albumin nanoparticles.

Figure 3. AFM images of DOX-loaded magnetic albumin nanoparticles: (A) 2D and (B) 3D pictures.

Figure 4. XRD spectrum of the (A) BSA-NPs and (B) M-BSA-NPs.

Figure 5. Magnetization curve of M-DOX-BSA nanoparticles.

Figure 6. In vitro release profile of DOX from (A) M-DOX-BSA nanoparticles cross-linked different GA ratio and (B) M-DOX-BSA nanoparticles in PBS medium with the absence or presence of proteolytic enzyme at pH 5, 6 and 7.4.